Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Oncode Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Oncode Institute, a foundation under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum, grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Ac...
Product Name : ABR-215050
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 02, 2022
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Oncode Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Active Biotech Strengthens the Patent Protection for Laquinimod in Eye Disorders
Details : Laquinimod is a first-in-class immunomodulator that induces immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment.
Product Name : ABR-215062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Preclinical Tasquinimod Data Presented at ASH 2021 Available on Active Biotech’s Website
Details : Preclinical data on drug tasquinimod, a small molecule immunomodulator Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.
Product Name : ABR-215050
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2021
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : NeoTX Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.
Product Name : ABR-217620
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
November 30, 2021
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : NeoTX Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod
Details : A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects.
Product Name : ABR-215062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 12, 2021
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : NeoTX Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Active Biotech Provides Status Update of its Clinical Naptumomab Project
Details : The study was amended to also include assessment of pre-treatment with obinutuzumab to assess its effect on anti-drug antibodies (ADAs) to naptumomab.
Product Name : ABR-217620
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 07, 2021
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : NeoTX Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.
Product Name : ABR-215050
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2021
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : NeoTX Therapeutics
Deal Size : $71.0 million
Deal Type : Licensing Agreement
Active Biotech Receive Milestone Payment From Neotx
Details : In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications.
Product Name : ABR-217620
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
November 12, 2020
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : NeoTX Therapeutics
Deal Size : $71.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Active Biotech announces new direction
Details : Tasquinimod will be advanced in a new academic partnership, as an immunomodulatory product with a novel mechanism of action, for the treatment of multiple myeloma.
Product Name : ABR-215050
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2020
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary objective of the study is to establish the optimal dose and treatment schedule of tasquinimod when used as a single agent and in combination with IRd.
Product Name : ABR-215050
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2020
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable